Bicycle Therapeutics (NASDAQ: BCYC) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.59) by 22.03 percent. This is a 36.84 percent increase over losses of $(1.14) per share from the same period last year. The company reported quarterly sales of $629.000 thousand which missed the analyst consensus estimate of $4.221 million by 85.10 percent. This is a 78.46 percent decrease over sales of $2.920 million the same period last year.